Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis.
Difei Lu, Na Li, Zhenfang Yuan et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis examined the weight loss effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual agonists in 40,408 participants across 32 trials. The analysis found a weighted mean weight reduction of 9.36% (95% CI 7.92%-10.80%) with significant interstudy heterogeneity. Factors such as baseline anxiety/depression positively influenced weight loss, while comorbidities like Type 2 diabetes negatively impacted treatment response.
Key findings
- GLP-1RAs and dual agonists achieved a mean weight reduction of 9.36%.
- Longer treatment duration (≥ 72 weeks) resulted in superior weight loss effects.
- Baseline anxiety/depression was positively associated with weight loss efficacy (β = 2.44).
- Comorbidities like T2DM, OSA, and MAFLD negatively correlated with treatment response.
Why it matters
Understanding the factors influencing weight loss heterogeneity in obesity treatments can guide personalized management strategies. Clinicians can tailor interventions based on individual patient characteristics, potentially improving treatment outcomes.